Literature DB >> 9705337

Incorporation and excision of 9-(2-phosphonylmethoxyethyl)guanine (PMEG) by DNA polymerase delta and epsilon in vitro.

P Kramata1, K M Downey, L R Paborsky.   

Abstract

PMEG (9-(2-phosphonylmethoxyethyl)guanine) is an acyclic nucleotide analog being evaluated for its anti-proliferative activity. We examined the inhibitory effects of PMEG diphosphate (PMEGpp) toward DNA polymerases (pol) delta and epsilon and found it to be a competitive inhibitor of both these enzymes. The apparent Ki values for PMEGpp were 3-4 times lower than the Km values for dGTP. The analog was shown to function as a substrate and to be incorporated into DNA by both enzymes. Examination of the ability of pol delta and pol epsilon to repair the incorporated PMEG revealed that pol epsilon could elongate PMEG-terminated primers in both matched and mismatched positions with an efficiency equal to 27 and 85% that observed for dGMP-terminated control template-primers. Because PMEG acts as an absolute DNA chain terminator, the elongation of PMEG-terminated primers is possible only by cooperation of the 3'-5'-exonuclease and DNA polymerase activities of the enzyme. In contrast to pol epsilon, pol delta exhibited negligible activity on these template-primers, indicating that pol epsilon, but not pol delta, can repair the incorporated analog.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9705337     DOI: 10.1074/jbc.273.34.21966

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  Tenofovir diphosphate is a poor substrate and a weak inhibitor of rat DNA polymerases alpha, delta, and epsilon*.

Authors:  Gabriel Birkus; Miroslav Hájek; Pavel Kramata; Ivan Votruba; Antonín Holý; Berta Otová
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Enhanced topical and transdermal delivery of antineoplastic and antiviral acyclic nucleoside phosphonate cPr-PMEDAP.

Authors:  Kateřina Vávrová; Petra Kovaříková; Barbora Skolová; Martina Líbalová; Jaroslav Roh; Robert Cáp; Antonín Holý; Alexandr Hrabálek
Journal:  Pharm Res       Date:  2011-06-14       Impact factor: 4.200

3.  Antiproliferative effects of octadecyloxyethyl 9-[2-(phosphonomethoxy)ethyl]guanine against Me-180 human cervical cancer cells in vitro and in vivo.

Authors:  Nadejda Valiaeva; Julissa Trahan; Kathy A Aldern; James R Beadle; Karl Y Hostetler
Journal:  Chemotherapy       Date:  2010-03-08       Impact factor: 2.544

4.  Role of cathepsin A and lysosomes in the intracellular activation of novel antipapillomavirus agent GS-9191.

Authors:  Gabriel Birkus; Nilima Kutty; Christian R Frey; Riri Shribata; Tsuifen Chou; Carston Wagner; Martin McDermott; Tomas Cihlar
Journal:  Antimicrob Agents Chemother       Date:  2011-03-07       Impact factor: 5.191

5.  Genetic and physical interactions between DPB11 and DDC1 in the yeast DNA damage response pathway.

Authors:  Hong Wang; Stephen J Elledge
Journal:  Genetics       Date:  2002-04       Impact factor: 4.562

6.  Impact of 2-bromo-5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole riboside and inhibitors of DNA, RNA, and protein synthesis on human cytomegalovirus genome maturation.

Authors:  Michael A McVoy; Daniel E Nixon
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

7.  GS-9191 is a novel topical prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)guanine with antiproliferative activity and possible utility in the treatment of human papillomavirus lesions.

Authors:  Grushenka H I Wolfgang; Riri Shibata; Jianying Wang; Adrian S Ray; Sylvia Wu; Edward Doerrfler; Hans Reiser; William A Lee; Gabriel Birkus; Neil D Christensen; Graciela Andrei; Robert Snoeck
Journal:  Antimicrob Agents Chemother       Date:  2009-04-27       Impact factor: 5.191

8.  Phase II evaluation of VDC-1101 in canine cutaneous T-cell lymphoma.

Authors:  M A Morges; J H Burton; C F Saba; D M Vail; K E Burgess; D H Thamm
Journal:  J Vet Intern Med       Date:  2014 Sep-Oct       Impact factor: 3.333

9.  A novel lipid prodrug strategy for sustained delivery of hexadecyloxypropyl 9-[2-(phosphonomethoxy)ethyl]guanine (HDP-PMEG) on unwanted ocular proliferation.

Authors:  Mei Chen; Jiangping Hou; Guilin Tan; Peng Xie; William R Freeman; James R Beadle; Karl Y Hostetler; Lingyun Cheng
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

10.  GS-9219/VDC-1101--a prodrug of the acyclic nucleotide PMEG has antitumor activity in spontaneous canine multiple myeloma.

Authors:  Douglas H Thamm; David M Vail; Ilene D Kurzman; Darius Babusis; Adrian S Ray; Noel Sousa-Powers; Daniel B Tumas
Journal:  BMC Vet Res       Date:  2014-01-25       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.